Storm G, Crommelin D J
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
Hybridoma. 1997 Feb;16(1):119-25. doi: 10.1089/hyb.1997.16.119.
The potential and limitations of targeted delivery of anticancer agents with colloidal particulate carriers is the subject of this contribution. Because over the years liposomes have gained the most attention as carrier system in the category of colloidal carrier systems, this paper focuses on the utility of the liposomal system for tumor targeting. It is imperative that an intended therapeutic application of liposomes should be well matched with the liposome behavior in vivo. Therefore, the in vivo fate of the first-generation liposomes and the more recently developed second-generation liposomes (surface-modified liposomes such as the immunoliposomes and long-circulating liposomes) is analyzed in terms of accessibility of target sites, time-, and site-controlled drug release and potential target sites for rational targeted delivery are discussed. A few examples of areas in cancer chemotherapy, with a strong rationale for the use of liposomes, are given. It is concluded that, although several options are available on the drawing board, issues such as tumor cell heterogeneity, access to the target site, shedding of antigens, and target site-specific release of the liposome-associated drug need to be addressed early in the development process.
本文探讨了使用胶体颗粒载体靶向递送抗癌药物的潜力和局限性。多年来，脂质体作为胶体载体系统中最受关注的载体系统，因此本文重点关注脂质体系统在肿瘤靶向中的应用。脂质体的预期治疗应用必须与体内脂质体行为相匹配。因此，从靶位点的可达性、时间和位点控制的药物释放方面分析了第一代脂质体和最近开发的第二代脂质体（如免疫脂质体和长循环脂质体等表面修饰脂质体）的体内命运，并讨论了合理靶向递送的潜在靶位点。给出了癌症化疗中一些有充分理由使用脂质体的领域的例子。得出的结论是，尽管在规划中有几种选择，但在开发过程早期就需要解决肿瘤细胞异质性、进入靶位点、抗原脱落以及脂质体相关药物的靶位点特异性释放等问题。
